WallStreetZenWallStreetZen

NASDAQ: ETRA
Electra Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ETRA

Based on 3 analysts offering 12 month price targets for Electra Therapeutics Inc

Min Forecast
$30.00+276.41%
Avg Forecast
$32.67+309.87%
Max Forecast
$36.00+351.69%

Should I buy or sell ETRA stock?

Based on 5 analysts offering ratings for Electra Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ETRA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ETRA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their ETRA stock forecasts and price targets.

ETRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-23
lockedlocked$00.00+00.00%2026-10-22
lockedlocked$00.00+00.00%2026-10-13
lockedlocked$00.00+00.00%2026-10-13
lockedlocked$00.00+00.00%2026-10-13
Cantor Fitzgerald
Top 4%
97
Strong BuyInitiates Coverage OnN/AN/A2026-10-13

1 of 1

Forecast return on equity

Is ETRA forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ETRA forecast to generate an efficient return on assets?

Company
-138.93%
Industry
-4.1%
ETRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ETRA earnings per share forecast

What is ETRA's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$3.41
Avg 2 year Forecast
-$2.13
Avg 3 year Forecast
-$2.42

ETRA revenue forecast

What is ETRA's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ETRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AARD$1.26$5.60+344.44%Hold
ABVC$1.00N/AN/A
ABVX$89.49$154.55+72.70%Strong Buy
ACET$3.10$42.75+1,279.03%Strong Buy
KRSA$30.56$52.33+71.25%Strong Buy
View Top Biotech Stocks

Electra Therapeutics Stock Forecast FAQ

Is Electra Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ETRA) stock is to Strong Buy ETRA stock.

Out of 5 analysts, 4 (80%) are recommending ETRA as a Strong Buy, 1 (20%) are recommending ETRA as a Buy, 0 (0%) are recommending ETRA as a Hold, 0 (0%) are recommending ETRA as a Sell, and 0 (0%) are recommending ETRA as a Strong Sell.

If you're new to stock investing, here's how to buy Electra Therapeutics stock.

What is ETRA's earnings growth forecast for 2026-2028?

(NASDAQ: ETRA) Electra Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.03%.

Electra Therapeutics's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast ETRA's earnings for 2026 to be -$208,529,173, with the lowest ETRA earnings forecast at -$375,436,830, and the highest ETRA earnings forecast at -$123,178,181. On average, 8 Wall Street analysts forecast ETRA's earnings for 2027 to be -$129,941,982, with the lowest ETRA earnings forecast at -$148,498,140, and the highest ETRA earnings forecast at -$107,780,908.

In 2028, ETRA is forecast to generate -$147,954,347 in earnings, with the lowest earnings forecast at -$182,628,761 and the highest earnings forecast at -$115,479,544.

What is ETRA's revenue growth forecast for 2026-2028?

(NASDAQ: ETRA) Electra Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 41.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.04%.

Electra Therapeutics's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast ETRA's revenue for 2026 to be $0, with the lowest ETRA revenue forecast at $0, and the highest ETRA revenue forecast at $0. On average, 8 Wall Street analysts forecast ETRA's revenue for 2027 to be $0, with the lowest ETRA revenue forecast at $0, and the highest ETRA revenue forecast at $0.

In 2028, ETRA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ETRA's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: ETRA) forecast ROA is -138.93%, which is lower than the forecast US Biotechnology industry average of -4.1%.

What is ETRA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year ETRA price target, the average ETRA price target is $32.67, with the highest ETRA stock price forecast at $36.00 and the lowest ETRA stock price forecast at $30.00.

On average, Wall Street analysts predict that Electra Therapeutics's share price could reach $32.67 by Oct 23, 2027. The average Electra Therapeutics stock price prediction forecasts a potential upside of 309.87% from the current ETRA share price of $7.97.

What is ETRA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ETRA) Electra Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that ETRA's EPS will be -$3.41 for 2026, with the lowest EPS forecast at -$6.14, and the highest EPS forecast at -$2.02. On average, analysts forecast that ETRA's EPS will be -$2.13 for 2027, with the lowest EPS forecast at -$2.43, and the highest EPS forecast at -$1.76. In 2028, ETRA's EPS is forecast to hit -$2.42 (min: -$2.99, max: -$1.89).

What is ETRA's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: ETRA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.